BCLI

BCLI is a pre-revenue clinical-stage biotech that has never earned a dollar since inception in 2000, and its balance sheet is now past distressed into functionally insolvent. FY2025 total assets are just $1.02M against $11.0M of liabilities, leaving stockholders' equity at -$9.98M (liabilities/equity of -1.10x). Cash & equivalents collapsed to $29K — not a typo, twenty-nine thousand dollars — down 84.5% YoY, while current liabilities of $11.0M dwarf current assets of $307K. The 10-K states outright that 'there is substantial doubt about our ability to continue as a going concern,' and that the stock has been delisted from Nasdaq to the OTCQB Venture Market, cutting off the ATM facility it previously leaned on. This is a company operating hand-to-mouth between financings.

The 'improving' headline numbers are a mirage created by shrinkage, not progress. Net loss narrowed to -$10.3M (from -$11.6M) and R&D fell 10.2% to $4.17M — but management attributes the R&D decline to cutting clinical-activity suppliers, materials and clean-room facilities, i.e. spending less on the very drug development that is the entire thesis. The 51.9% 'improvement' in diluted EPS to -$1.11 is an artifact of the share count exploding: weighted shares nearly doubled (5.0M to 9.3M) and shares outstanding rose 69.2% to 11.0M as the company issued stock to employees, sold shares under a distribution agreement, and did a private placement. Accumulated deficit stands at -$237M. Shareholders are being diluted continuously to fund operations, and management explicitly lists 'additional public and private sales of Common Stock and warrants... convertible promissory notes' as the plan going forward.